Discussion on the monthly treatment cost of lorlatinib/lorlatinib

Lorlatinib, also known as lorlatinib (Lorlatinib), is a third-generation ALK tyrosine kinase inhibitor (TKI) that has attracted much attention in recent years. Its unique structure gives it excellent blood-brain barrier penetration, allowing it to exhibit excellent anti-tumor effects in the treatment of advanced ALK-positive non-small cell lung cancer. Compared with second-generation ALK inhibitors, lorlatinib responds more comprehensively to ALK resistance mutations.

Lorlatinib is usually available to patients in the form of oral tablets. Common tablet specifications on the market include25mg and 100mg. The standard daily dosage is 100 mg, and in most cases, patients need to take one tablet daily. Of course, actual dosage may be adjusted based on the patient's specific condition and physician's orders.

In the Chinese market, lorlatinib has obtained marketing authorization and has been included in the scope of medical insurance. It provides patients with two main packaging specifications: 25mg×90 tablets and 100mg×30 tablets. Generally speaking, a patient's monthly dosage is approximately equivalent to one box of medication. Judging from the current domestic market pricing, the price range of original drugs is about 10,000 to 20,000 yuan, and even some high-priced products can reach 30,000 to 50,000 yuan per box, which undoubtedly increases the financial pressure on patients.

For patients with relatively tight financial conditions, overseas generic drugs have become an affordable alternative. By using the generic version of lorlatinib, patients’ monthly drug costs can be significantly reduced to approximately RMB 2,000. Compared with original drugs, the price advantage of generic drugs is obvious, which undoubtedly provides substantial help in reducing the financial burden of patients.